The Non-linear Relationship Between Normal Range Systolic Blood Pressure and Cardiovascular or All-Cause Mortality Among Elderly Population

Shuo Sun 1, Xiao-cong Liu 1, Guo-dong He 1, Kenneth Lo 2,3, Ying-qing Feng 1* and Yu-qing Huang 1*

1 Department of Cardiology, Guangdong Provincial People's Hospital, Guangdong Cardiovascular Institute, Guangdong Academy of Medical Sciences, Guangzhou, China, 2 Department of Epidemiology, Centre for Global Cardio-Metabolic Health, Brown University, Providence, RI, United States, 3 Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Hong Kong, China

Purpose: The aim was to explore the association of normal range SBP with cardiovascular and all-cause mortality in older adults without hypertension.

Methods: Participants aged ≥ 65 years without hypertension and those had an SBP level between 90 and 129 mmHg were included from the National Health and Nutrition Examination Survey (1999–2014). SBP was categorized into: 90–99, 100–109, 110–119, and 120–129 mmHg. Multivariate Cox regression was performed with hazard ratio (HR) and 95% confidence interval (CI).

Results: Of the 1,074 participants, 584 were men (54.38%). Compared with participants with SBP level ranged 110 to 119 mmHg, the HRs for all-cause mortality risk was 1.83 (95% CI: 1.04, 3.23) for SBP level ranged 90 to 99 mm Hg, 0.87 (95% CI: 0.54, 1.41) for SBP level ranged 100 to 109 mmHg, and 1.30 (95% CI: 0.96, 1.75) for SBP level ranged 120 to 129 mm Hg (P for trend = 0.448), and the HR for cardiovascular mortality risk was 3.30 (95% CI: 0.87, 12.54) for SBP level ranged 90 to 99 mmHg, 0.35(95% CI: 0.08, 1.56) for SBP level ranged 100 to 109 mmHg, and 1.75 (95% CI: 0.78, 3.94) for SBP level ranged 120 to 129 mm Hg (P for trend = 0.349) after confounders were adjusted.

Conclusion: These were a nonlinear association of normal range SBP level with all-cause and cardiovascular death in older adults.

Keywords: normal blood pressure, systolic blood pressure, elderly population, cardiovascular mortality, all-cause mortality

INTRODUCTION

Hypertension is one of the most common chronic diseases and remains the leading cause of death in worldwide (1). Hypertension is generally defined as having a systolic blood pressure (SBP) ≥ 140 mmHg and/or a diastolic blood pressure (DBP) ≥ 90 mmHg, and prehypertension was a SBP of 120–139 mmHg and/or a DBP of 80–89 mmHg (2–5). In addition, prehypertension was further divided into low (120–129/80–84 mmHg) and high (130–139/80–89 mmHg) prehypertension,
Several previous meta-analyses demonstrated the increased risk for cardiovascular diseases (CVD) in people with low-range prehypertension, and a higher risk for mortality despite adjusting for cardiovascular risk factors (7–10). Furthermore, a recent study showed an increment of the risk of incident CVD with increasing SBP levels in persons without hypertension nor other traditional atherosclerotic cardiovascular disease risk factors (11). However, previous studies were mainly conducted among young and middle-aged population, but the evidence for older adults aged ≥ 65 years is lacking. Importantly, in 2017, the definition of hypertension has been adjusted to 130/80 mm Hg with a SBP/DBP by the American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Clinical Practice Guidelines (12). These changes were largely driven by the increasing importance of hypertension control in preventing CVD (12, 13). Importantly, among elderly population free of hypertension, the association of 2017 ACC/AHA elevated hypertension (120–129/80 mmHg) and normal blood pressure (<120/80 mmHg) with the risk of mortality were still unclear. To address the knowledge gap, the aim of the present study was to explore the association of SBP level with cardiovascular and all-cause mortality in elderly population without hypertension.

METHODS

Study Population
All participants were included from the 1999–2014 National Health and Nutrition Examination Surveys (NHANES).

NHANES was an ongoing nationally representative study with a series of stratified, multistage probability surveys on United States civilian, non-institutionalized population, which was conducted by the National Center for Health Statistics of the Center for Disease Control and Prevention (14, 15). We enrolled subjects aged ≥ 65 years old. However, participants aged < 65 years, with missing data on follow-up, blood pressure, blood lipid, height and weight, past medical history, education level, marital status and smoking status at baseline were excluded. In addition, participants with hypertension and SBP < 90 mmHg were also excluded. Finally, a total of 1,074 participants were included for data analysis (Figure 1). The survey protocol was approved by the Institutional Review Board of the Centers for Disease Control and Prevention. All participants have provided written informed consent.

Blood Pressure Measurement
Details of blood pressure measurement was described previously (15, 16). In brief, it was measured by a trained physician using a mercury sphygmomanometer [W. A. Baum Co. Inc (1050), Copiague, New York, USA] and an appropriately sized cuff. Three consecutive blood pressure readings were obtained from the same arm. SBP and diastolic blood pressure (DBP) were defined as the average value of three blood pressure measurements. Hypertension was defined as a previous diagnosis by a physician, and/or SBP/DBP ≥ 130/80 mmHg, and/or currently taking antihypertensive medications according to the 2017 ACC/AHA hypertension guideline (12). SBP level ranged from 90 to 129 mmHg was considered normal range. Participants

FIGURE 1 | Research flow chart.
were divided into four groups according to baseline SBP: 90–99, 100–109, 110–119, and 120–129 mmHg.

**Covariate Assessment**
Data from questionnaires and physical examination were obtained according to a standardized procedure. Age, sex, race, marital status, smoking status, educational level, and history of comorbidities (including hypertension, diabetes, CVD and cancer) were self-reported during in-person interview. Medication history was obtained from self-report and the questions on prescribed medications. Other covariates included height, weight, total cholesterol, high-density lipoprotein cholesterol were also assessed. Body mass index (BMI) was defined as mass (kg) divided by the square of height (m²). Diabetes was defined as having a history of diabetes, or taking hypoglycemic medications currently, or fasting blood glucose

**TABLE 1 | Demographic and clinical characteristics according to normal systolic blood pressure levels.**

| Systolic blood pressure, mmHg | Total | 90–99 | 100–109 | 110–119 | 120–129 | P-value |
|-------------------------------|-------|-------|---------|---------|---------|---------|
| Number | 1074  | 41    | 162     | 401     | 470     |         |
| Age, years | 72.20 ± 5.62 | 72.02 ± 5.33 | 71.86 ± 5.51 | 71.76 ± 5.49 | 72.71 ± 5.76 | 0.074 |
| Sex, n (%) | 0.774 |       |         |         |         |         |
| Male | 584 (54.38) | 20 (48.78) | 86 (52.47) | 224 (55.86) | 255 (54.26) |         |
| Female | 490 (45.62) | 21 (51.22) | 77 (47.53) | 177 (44.14) | 215 (45.74) |         |
| Race, n (%) | 0.593 |       |         |         |         |         |
| Non-white | 396 (36.87) | 11 (26.83) | 60 (37.04) | 148 (36.91) | 177 (37.66) |         |
| White | 678 (63.13) | 30 (73.17) | 102 (62.96) | 253 (63.09) | 293 (62.34) |         |
| Marital status, n (%) | 0.813 |       |         |         |         |         |
| Married | 415 (38.64) | 16 (39.02) | 68 (41.98) | 151 (37.66) | 180 (38.30) |         |
| Other | 659 (61.36) | 25 (60.98) | 94 (58.02) | 250 (62.34) | 290 (61.70) |         |
| Education level, n (%) | 0.226 |       |         |         |         |         |
| Less than high school | 346 (32.22) | 11 (26.83) | 44 (27.16) | 126 (31.42) | 165 (35.11) |         |
| High school or above | 728 (67.78) | 30 (73.17) | 118 (72.84) | 275 (68.58) | 305 (64.89) |         |
| Smoking, n (%) | 0.596 |       |         |         |         |         |
| No | 487 (45.34) | 19 (46.34) | 76 (46.91) | 171 (42.64) | 221 (47.02) |         |
| Yes | 587 (54.66) | 22 (53.66) | 86 (53.09) | 230 (57.36) | 249 (52.98) |         |
| Body mass index, kg/m² | 26.40 ± 4.79 | 25.03 ± 5.22 | 25.69 ± 5.06 | 26.58 ± 4.75 | 26.61 ± 4.66 | 0.038 |
| Systolic blood pressure, mmHg | 117.18 ± 8.47 | 95.86 ± 2.50 | 105.84 ± 2.79 | 115.07 ± 2.94 | <0.001 |
| Diastolic blood pressure, mmHg | 63.21 ± 11.53 | 53.64 ± 13.65 | 60.17 ± 12.01 | 63.31 ± 10.66 | <0.001 |
| Total cholesterol, mg/dl | 203.68 ± 39.41 | 215.44 ± 48.47 | 198.57 ± 38.88 | 201.32 ± 36.87 | 206.43 ± 40.52 | 0.018 |
| HDL cholesterol, mg/dl | 56.17 ± 16.49 | 62.98 ± 19.84 | 58.03 ± 14.96 | 54.81 ± 16.01 | 56.09 ± 16.93 | 0.008 |

**Comorbidities, n (%)**

**Diabetes**
| No | 913 (85.01) | 37 (90.24) | 140 (88.42) | 347 (86.53) | 389 (82.77) |         |
| Yes | 161 (14.99) | 4 (9.76) | 22 (13.58) | 54 (13.47) | 81 (17.23) |         |

**Cardiovascular disease**
| No | 969 (90.22) | 37 (90.24) | 143 (88.27) | 364 (90.77) | 425 (90.43) |         |
| Yes | 105 (9.78) | 4 (9.76) | 19 (11.73) | 37 (9.23) | 45 (9.57) |         |

**Cancer**
| No | 839 (78.12) | 29 (70.73) | 123 (75.93) | 319 (79.55) | 368 (78.30) |         |
| Yes | 235 (21.88) | 12 (29.27) | 39 (24.07) | 82 (20.45) | 102 (21.70) |         |

**Outcomes, n (%)**

**Cardiovascular disease mortality**
| No | 1027 (95.62) | 38 (92.68) | 159 (98.15) | 386 (96.26) | 444 (94.47) |         |
| Yes | 47 (4.38) | 3 (7.32) | 3 (1.85) | 15 (3.74) | 26 (5.53) |         |

**All-cause mortality**
| No | 794 (73.93) | 25 (60.98) | 131 (80.86) | 313 (78.05) | 325 (69.15) |         |
| Yes | 280 (26.07) | 16 (39.02) | 31 (19.14) | 88 (21.95) | 145 (30.85) |         |

n, number; HDL, high density lipoprotein.
Values are mean ± standardized differences or n (%).
level ≥ 7.0 mmol/l (126 mg/dl), or hemoglobin A1c (HbA1C) level ≥ 6.5% (17). Further details of data collection can be found in https://wwwn.cdc.gov/nchs/nhanes/Default.aspx.

**Outcomes**

Outcomes of this study mainly were all-cause and cardiovascular mortality as obtained from a publicly available dataset of the NHANES. The database captured the vital status and cause of death of survey subjects from baseline to 31 December 2015 which came first (16). Cardiovascular mortality was defined according to the International Classification of Diseases, 10th Edition, Clinical Modification System codes (I00–I09, I11, I13, I20–I51, and I60–I69) derived from death-certificate data.

**Statistical Analysis**

Baseline characteristics are presented as mean ± standard deviation (continuous variables) or percentage (categorical variables) as appropriate. We compared baseline characteristics among participants according to SBP level using Chi-square for categorical variables, and Analysis of Variance for continuous variables.}

![Figure 2](https://example.com/figure2.png)

**FIGURE 2 | A,B** Kaplan-Meier analysis for the incidence of mortality among groups of different normal systolic blood pressure level. SBP, systolic blood pressure.
and prehypertension status with all-cause and cardiovascular mortality were also tested. Given the inherent nature of multiple complex survey designs, we accounted for sample weight for each participant in the NHANES dataset. We used svydesign function in R to account for sampling weights, as well as the stratification and clustering. A 2-sided \( P < 0.05 \) was considered statistically significant. All statistical analyses were performed using R version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria).

**RESULTS**

**Baseline Characteristics**

The baseline demographic characteristics were presented in Table 1. The study population included 1,074 subjects [584 (54.38%) male], average age was 72.20 ± 5.62 years. Participants with higher SBP level also had higher BMI, total cholesterol and DBP. However, there were no significant differences in age, sex, race, marital status, education level, smoking status, and comorbidities among SBP groups.

**The Relationship Between Systolic Blood Pressure and Mortality**

During a median follow-up of 89.41 months, 47 (4.38%) cases of cardiovascular and 280 (26.07%) cases of all-cause mortality were observed, respectively. In addition, among all the 1,074 participants, there were 16 (39.02%), 31 (19.14%), 88 (21.95%) and 145 (30.85%) cases of all-cause mortality occurred ranging from 90–99 mmHg for SBP, 100–109 mmHg, 110–119 mmHg to 120–129 mmHg (\( P < 0.001 \)), and 3 (7.32%), 3 (1.85%), 15 (3.74%), 26 (5.53%) cases of cardiovascular mortality occurred, respectively, among the above four groups (\( P = 0.158 \)). Figure 2 showed the Kaplan-Meier mortality rate by the groups according to SBP level. The log-rank test revealed that there was a significant difference among each group of SBP in all-cause mortality (Figure 2A) and cardiovascular mortality (Figure 2B).

As shown in Figure 3, the multivariate restrictive cubic curves showed that SBP has a non-linear relationship with all-cause (Figure 3A) and cardiovascular (Figure 3B) mortality, respectively. In addition, the risk of mortality may be the lowest when the SBP range from 110 to 119 mmHg. As shown in Table 2, when SBP was treated as a continuous variable, SBP has no obvious relationship with all-cause and cardiovascular mortality regardless of confounder adjustments (all \( P > 0.05 \)). However, when SBP was referred as a categorical variable, compared with participants with an SBP level of 110 to 119 mmHg, there seemed to be a significantly higher risk for all-cause mortality among participants with an SBP level of 90–99 mmHg (HR, 1.56; 95% CI, 0.86, 2.82) and 120 to 129 mmHg (HR, 1.36; 95% CI, 1.03, 1.80) (\( P \) for trend = 0.113) in Model I. In Model III where age, sex, race, marital status, education level, smoking, body mass index, DBP, total cholesterol, high density lipoprotein cholesterol, and comorbidities (diabetes, CVD, and cancer) were adjusted, similar increment of all-cause mortality risk was observed among participants with an SBP level of 90
to 99 mmHg (HR, 1.83; 95% CI, 1.04, 3.23; P = 0.037) and 120 to 129 mmHg (HR, 1.30; 95% CI, 0.96, 1.75; P = 0.086) (P for trend = 0.448). As for cardiovascular mortality, all-cause mortality risk was also seemed to be higher among participants with an SBP level of 90 to 99 mmHg (HR, 3.30; 95% CI, 0.87, 12.54; P = 0.080) and 120 to 129 mmHg (HR, 1.75; 95% CI, 0.78, 3.94; P = 0.176), but the association did not reach statistical significance.

Subgroup Analysis
The result of subgroup analysis was shown in Table 3. Compared to the reference group (SBP: 110–119 mmHg), participants with the level of SBP 90–99 mmHg had a higher risk of all-cause mortality among female population compared to male population (HR: 3.08 vs. 1.89), for people with BMI ≥ 25 compared to BMI < 25 kg/m² (HR: 3.12 vs. 1.09) and those without diabetes compared to those with diabetes (HR: 2.23 vs. 0.67). Similar results were also found in participants with the level of SBP was 120–129 mmHg. When the level of SBP was 90–99 mmHg, and compared to the reference group, we only found the risk for cardiovascular mortality might be higher in people with BMI ≥ 25 kg/m² (HR, 2.93; 95% CI, 1.19, 7.21; P = 0.019). In addition, we found that only BMI interacted significantly with the association between SBP and cardiovascular mortality (P for interaction = 0.012), while there was no interaction between sex, race, diabetes status and cardiovascular and all-cause mortality (all P-interaction > 0.05).

DISCUSSION
The main findings from the present study of older individuals with normal blood pressure were (1) when SBP < 115 mmHg, as SBP decreased, the risk of mortality gradually increased, and when SBP ≥ 115 mmHg the risk of mortality gradually increased with SBP level. The appropriate SBP level is probably 110–120 mmHg. (2) The risk for cardiovascular mortality was increased at a SBP ≥ 115 mmHg. (3) Although SBP was in the normal range, relatively higher or lower SBP levels have a higher risk of mortality in women and population with overweight or obesity. (4) The relationship between normal SBP and all-cause mortality was differed by sex, race, BMI, and the history of diabetes. (5) The SBP level in the normal range might have dose-response relationship with all-cause and cardiovascular mortality.

Our findings were consistent with a prior meta-analysis of individual data for one million adults in 61 prospective studies, which demonstrated that usual SBP ≥ 115 mm Hg might significantly elevate the risk for all-cause and cardiovascular mortalities.

### TABLE 2 | Multivariate Cox regression analysis of normal systolic blood pressure with mortality.

| SBP group, mmHg | Number | Model I HR (95%CI), P-value | Model II HR (95%CI), P-value | Model III HR (95%CI), P-value |
|-----------------|--------|-----------------------------|-------------------------------|-------------------------------|
| 90–99           | 41     | 1.56(0.86,2.82)0.145         | 2.01(1.03,3.94)0.022          | 1.83(1.04,3.33)0.037          |
| 100–109         | 162    | 0.81(0.50,1.29)0.367         | 0.89(0.56,1.43)0.636          | 0.87(0.54,1.41)0.581          |
| 110–119         | 401    | 1.0                          | 1.0                           | 1.0                           |
| 120–129         | 470    | 1.36(1.03,1.8)0.031          | 1.27(0.96,1.68)0.089          | 1.30(0.96,1.75)0.086          |
| P for trend     |        | 0.113                        | 0.592                         | 0.448                         |

SBP, systolic blood pressure; HR, hazard ratio; CI, confidence interval. Model I adjust for none. Model II adjust for age, sex, and race. Model III adjust for age, sex, race, marital status, education level, smoking, body mass index, diastolic blood pressure, total cholesterol, high density lipoprotein cholesterol, and comorbidities (diabetes, cardiovascular disease, and cancer).
### TABLE 3 | Subgroups analyses of normal systolic blood pressure with mortality.

| Characteristic | Number | 90–99 | 100–109 | 110–119 | 120–129 | P-interaction |
|----------------|--------|-------|---------|---------|---------|--------------|
| **All-cause mortality** |        |       |         |         |         |              |
| Sex | 584 | 1.58(0.76,3.27) | 0.219 | 0.65(0.38,1.10) | 0.108 | 1.0(0.69,1.47) | 0.972 |
| Male | 490 | 3.01(1.31,6.94) | 0.010 | 1.45(0.56,3.75) | 0.446 | 1.0(0.98,3.62) | 0.059 |
| Female | 396 | 3.08(0.78,12.07) | 0.107 | 0.97(0.40,2.35) | 0.943 | 1.90(0.96,3.76) | 0.066 |
| Race | 678 | 1.89(0.93,3.54) | 0.039 | 0.91(0.53,1.69) | 0.732 | 1.27(0.91,1.77) | 0.157 |
| Non-white | 456 | 1.09(0.49,2.41) | 0.823 | 0.97(0.40,2.35) | 0.943 | 1.0(0.96,3.76) | 0.066 |
| White | 618 | 3.12(1.46,6.88) | 0.003 | 1.14(0.53,2.34) | 0.744 | 1.0(1.01,2.28) | 0.046 |
| Body mass index, kg/m² | 913 | 2.23(1.22,4.08) | 0.009 | 0.84(0.46,1.52) | 0.564 | 1.0(1.04,2.03) | 0.029 |
| ≥25 | 618 | 2.23(1.22,4.08) | 0.009 | 0.84(0.46,1.52) | 0.564 | 1.0(1.04,2.03) | 0.029 |
| Diabetes | 913 | 2.23(1.22,4.08) | 0.009 | 0.84(0.46,1.52) | 0.564 | 1.0(1.04,2.03) | 0.029 |
| No | 618 | 7.40(1.36,40.14) | 0.02 | 0.95(0.11,8.10) | 0.964 | 1.0(0.69,3.41) | 0.077 |
| Yes | 618 | 1.15(0.11,12.35) | 0.908 | 0.00(0.00,Inf) | 0.997 | 1.0(0.69,3.41) | 0.077 |

CI, confidence interval.

When analyzing a subgroup variable, age, sex, race, marital status, education level, smoking, body mass index, diastolic blood pressure, total cholesterol, high density lipoprotein cholesterol, and comorbidities (diabetes, cardiovascular disease, and cancer) were all adjusted except the variable itself.

...mortality (18). However, some studies have found that SBP (120–139 mmHg) did not significantly increase the risk of death among older population (19–21). Although we found that SBP >115 mmHg in the elderly might increase the mortality risk for older adults, it was still unclear whether blood pressure treatment should be initiated earlier. Currently, a large number of hypertension guidelines recommend pharmacological treatment to be initiated when SBP/DBP ≥140/90 mmHg in population aged ≥65 years, and if tolerable, the SBP can be reduced to <130 mm Hg (1, 3, 4). The post-analysis of the Felodipine Event Reduction (FEVER) trial found that when the average blood pressure level after treatment was lower than 120/70 mmHg, the risk of stroke, cardiac events and total death were the lowest (22). SBP intervention trial (SPRINT) also demonstrated that targeting a SBP of <120 mmHg compared to <140 mmHg could significantly result in the lower rates of fatal and non-fatal major cardiovascular events and all-cause mortality (23). However, for patients with type 2 diabetes, targeting a SBP of <120 mm Hg, as compared with <140 mm Hg, did not reduce the rate of a composite outcome of fatal and non-fatal major cardiovascular events (24). Therefore, more studies on blood pressure management among elderly may be needed in the future, which may help to refine the SBP target (<120 mmHg) for older adults in line with the results from SPRINT, JATOS, VALISH trials. Besides, our finding might suggest a lower blood pressure threshold to define hypertension in elderly people.

In addition, subgroup analysis showed that the relationship between normal SBP and all-cause mortality was differed by sex, race, overweight/obesity, and diabetes. A previous meta-analysis also showed a sex difference in the relationship between SBP and death in older population (18). Among ambulatory adults aged 75 years or older, treating to an SBP target of <120 mm Hg compared with an SBP target of <140 mm Hg has resulted in significantly lower rates of fatal and non-fatal major cardiovascular events and death from any cause (25). We found that SBP of 120–129 mm Hg might increase risk for all-cause mortality among subjects without diabetes, but SBP <120 mm Hg did not, and this observation was similar to previous studies (24, 26). We also found that older adults with BMI ≥25 kg/m² with a SBP of 120–129 mm Hg significantly increased the risk...
of all-cause and cardiovascular mortality. For the elderly with overweight or obesity, they might benefit more by having SBP < 120 mm Hg.

To cautiously interpret our findings, some limitations of the present study should be noted. First, the small sample size might limit the generalizability of findings. Second, SBP was only measured once at baseline. Third, multiple covariates self-reported, therefore recall bias was possible. Fourth, this study did not fully consider the residual confounding effects, for example, atherosclerotic cardiovascular disease score and physical activity and diet. Fifth, we only explored the association of SBP with mortality, but not with adverse CVD events. Sixth, in this study, very few participants aged ≥80 years, and there was no relevant data on frail, disability indices, and dementia/cognitive decline. Another limitation is that the cardiovascular event rate was low in a long follow-up, which is possible that the participants are normotensive at the beginning of study, therefore they have a lower risk of CVD over the years. Despite this issue, the direction of association between SBP and CVD mortality agrees with our overall findings. Besides, the present study had several strengths. On the one hand, NHANES have a rigorous and standardized study protocol, and have an extensive quality control procedure in data collection. On the other hand, the long period of follow up and the inclusion of multiple ethnic groups made this result reliable. Besides, this is one of the few studies to explore the relationship between SBP and all-cause and cardiovascular mortality in elderly normotensive subjects over such a long-term, prospective follow-up.

**CONCLUSIONS**

In conclusion, SBP might have a dose-response relationship with all-cause and cardiovascular mortality in older normotensive population. Despite having normal range of SBP, low SBP (90 to 99 mmHg) or elevated SBP (120 to 129 mmHg) might increase the risk of all-cause mortality for older adults. The blood pressure management of the elderly population should be individualized, and more attention needed to be paid to the elderly individuals without hypertension.

**DATA AVAILABILITY STATEMENT**

Publicly available datasets were analyzed in this study. This data can be found here: https://www.cdc.gov/nchs/nhanes/index.htm.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Institutional Review Board of the Centers for Disease Control and Prevention. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

All authors made substantial contributions to the conception and design, acquisition of data, or analysis and interpretation of data, took part in drafting the article or revising it critically for important intellectual content, agreed on the journal to which the article will be submitted, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

**FUNDING**

This research was supported by China International Medical Foundation- China Cardiovascular Disease Development Special Fund-Heart Health Research Fund (Z-2019-42-1908).

**REFERENCES**

1. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. *J Hypertens*. (2020) 38:982–1004. doi: 10.1097/HJH.0000000000002453
2. Bureau Of Disease Prevention and Control NHCO, Diseases NCFC, Chinese Academy Of Medical Science Peking Union Medical College FH, Prevention CCFC, Cardiology CSO, Committee CMDA, et al. [National guideline for hypertension management in China (2019)]. Zhonghua Xin Xue Guan Bing Za Zhi. (2020) 48:10–46. doi: 10.3760/cma.j.issn.0253-3758.2020.01.004
3. Williams B, Mancia G, Spiering W, Agabiti RE, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. (2018) 39:3021–104.
4. Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). *Hypertens Res*. (2014) 37:253–390. doi: 10.1038/hr.2014.20
5. Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, et al. Hypertension Canada’s 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults. *Can J Cardiol*. (2017) 33:557–76. doi: 10.1177/1715163517743525
6. Lee M, Saver JL, Chang B, Chang KH, Hao Q, Ovbiagele B. Presence of baseline prehypertension and risk of incident stroke: a meta-analysis. *Neurology*. (2011) 77:1330–7. doi: 10.1212/25WNL.0b013e3182315234
7. Huang Y, Cai X, Li Y, Su L, Mai W, Wang S, et al. Prehypertension and the risk of stroke: a meta-analysis. *Neurology*. (2014) 82:1153–61. doi: 10.1212/WNL.000000000000268
8. Han M, Li Q, Liu L, Zhang D, Ren Y, Zhao Y, et al. Prehypertension and risk of cardiovascular diseases: a meta-analysis of 47 cohort studies. *J Hypertens*. (2019) 37:2325–32. doi: 10.1097/HJH.0000000000002191
9. Huang Y, Cai X, Liu C, Zhu D, Hua J, Hu Y, et al. Prehypertension and the risk of coronary heart disease in Asian and Western populations: a meta-analysis. *J Am Heart Assoc*. (2015) 4:e001519. doi: 10.1161/JAHA.114.001519
10. Huang Y, Wang S, Cai X, Mai W, Hu Y, Tang H, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. *Bmc Med*. (2013) 11:177. doi: 10.1186/1741-7015-11-177
11. Whelton SP, McEvoy JW, Shaw L, Psaty BM, Lima J, Budoff M, et al. Association of normal systolic blood pressure level with cardiovascular disease in the absence of risk factors. *JAMA Cardiol*. (2020) 5:1011–8. doi: 10.1001/jamacardio.2020.1731
12. Whelton PK, Carey RM, Aronow WS, Casey DJ, Collins KJ, Dennison HC, et al. 2017 ACC/AHA/ABC/ACP/APhA/ASH/ASPC/NMA/PCNA
Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. (2018) 71:e127–e248. doi: 10.1016/HYP.0000000000000077

13. Qi Y, Han X, Zhao D, Wang W, Wang M, Sun J, et al. Long-term cardiovascular risk associated with stage 1 hypertension defined by the 2017 ACC/AHA hypertension guideline. J Am Coll Cardiol. (2018) 72:1201–10. doi: 10.1016/j.jacc.2018.06.056

14. de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of Familial Hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). Circulation. (2016) 133:1067–72. doi: 10.1161/CIRCULATIONAHA.115.018791

15. Huang YQ, Liu L, Lo K, Huang JY, Zhang B, Feng YQ. The relationship between mean telomere length and blood pressure: results from the National Health and Nutrition Examination Surveys. Ann Transl Med. (2020) 8:535. doi: 10.21037/atm.2020.03.205

16. Huang YQ, Liu L, Huang JY, Lo K, Chen CL, Yu YL, et al. Prehypertension and risk for all-cause and cardiovascular mortality by diabetes status: results from the national health and nutrition examination surveys. Ann Transl Med. (2020) 8:323. doi: 10.21037/atm.2020.02.144

17. Association AD. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. (2018) 41:S13–S27. doi: 10.2337/dk18-S002

18. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. (2002) 360:1903–13. doi: 10.1016/S0140-6736(02)11911-8

19. Okayama A, Kadokawa T, Okamura T, Hayakawa T, Ueshima H. Age-specific effects of systolic and diastolic blood pressures on mortality due to cardiovascular diseases among Japanese men (NIPPON DATA80). J Hypertens. (2006) 24:459–62. doi: 10.1097/HJH.0000209981.43983.cf

20. Mohebi R, Mohebi A, Ghanbarian A, Momenan A, Azizi F, Hadaegh F. Is systolic blood pressure below 150 mm Hg an appropriate goal for primary prevention of cardiovascular events among elderly population? J Am Soc Hypertens. (2014) 8:491–7. doi: 10.1016/j.jshh.2014.04.010

21. Hadaegh F, Mohebi R, Khalili D, Hasheminia M, Sheikholeslami F, Azizi F. High normal blood pressure is an independent risk factor for cardiovascular disease among middle-aged but not in elderly populations: 9-year results of a population-based study. J Hum Hypertens. (2013) 27:18–23. doi: 10.1038/jhh.2011.112

22. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. J Hypertens. (2005) 23:2157–72. doi: 10.1097/01.hjh.0000194120.42722.ac

23. Wright JJ, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. (2015) 373:2103–16. doi: 10.1056/NEJMoa1511939

24. Cushman WC, Evans GW, Byington RP, Gof GJ, Grimm RJ, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. (2010) 362:1575–85. doi: 10.1056/NEJMoa1001286

25. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs. standard blood pressure control and cardiovascular disease outcomes in adults aged ≧75 years: a randomized clinical trial. JAMA. (2016) 315:2673–82. doi: 10.1001/jama.2016.7050

26. Chugh A, Bakris G. Intensive lowering of systolic blood pressure to a target of less than 120 mm Hg has no effect on the rate of fatal and non-fatal major cardiovascular events in high-risk patients with type 2 diabetes. Evid Based Med. (2010) 15:142–3. doi: 10.1136/ebm1099

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Sun, Liu, He, Lo, Feng and Huang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.